A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

NCT02607202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Unknown Primary Tumors

Interventions

DRUG: nab-paclitaxel
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

Fondazione del Piemonte per l'Oncologia